Piercing the limits | Patenting in the age of needle-free vaccines
For more than a century, the needle and syringe have been the standard tools of immunisation. Now, advances in engineering and formulation are driving a shift toward needle-free vaccine...
For more than a century, the needle and syringe have been the standard tools of immunisation. Now, advances in...
Read More
Australia | Part 2: Regulatory considerations for orphan drugs
Following our first article on orphan drug development, which examined key patenting options and strategies, our second article sets out the key regulatory considerations in Australia. Orphan drug patent strategy...
Following our first article on orphan drug development, which examined key patenting options and strategies, our second article sets...
Read More
Australia | Part 1: Patenting orphan drugs
Collectively, rare diseases impact approximately 8% of the Australian population, or around 2 million people. Orphan drugs are pharmaceutical products developed to treat rare diseases, however with each drug...
Collectively, rare diseases impact approximately 8% of the Australian population, or around 2 million people. Orphan drugs are pharmaceutical...
Read More

Contact our Expert Team

Contact Us
Contact Us